



Association of absolute lymphocyte count and cancer incidence and mortality: the Atherosclerosis Risk in Communities (ARIC) study

Guillaume Onyeaghala¹, Anna E. Prizment^{1,2} Darek Lucas¹, Sarah Davidovics^{3,4}, Corinne E. Joshu^{3,4}, Elizabeth A. Platz³⁻⁵, Aaron R. Folsom¹, Kala Visvanathan^{3,4}

¹ Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN. ² Masonic Cancer Center, University of Minnesota, Minneapolis, MN. ³ Department of Epidemiology, John Hopkins Bloomberg School of Public Health, Baltimore, MD. ⁴ Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. ⁵ Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD

Introduction

• Several prospective studies have reported a positive association between total white blood cell (WBC) count, a non-specific marker of systemic inflammation, and cancer incidence and mortality.

• However, subtypes of total WBC count may have distinct roles in inflammation-mediated tumorigenesis

–This study focused on lymphocytes, a subtype of total white blood cells (WBC), which include B cells and T cells (part of the adaptive immune response), and natural killer (NK) cells (part of the innate immune response).

–In addition, we also examined the association of granulocytes, another broad subtype of total WBC, which are involved in the acute inflammatory response.

• Elevated lymphocyte and granulocyte levels may be subclinical inflammatory markers of the carcinogenic effects of common exposures, including obesity and cigarette smoke.

Goal of the study

• We hypothesized that higher circulating levels of pre-diagnostic lymphocyte count would be associated with higher cancer incidence and mortality in the Atherosclerosis Risk in Communities (ARIC) study.

Methods

• The ARIC study is a prospective cohort study conducted in four centers: Forsyth County, NC; Jackson, Mississippi; Minneapolis, MN; Washington County, MD.

• Participants received five exams in 1987-89, 1990-92, 1993-95, 1996-98, and 2011-2013, which included medical examination and questionnaires.

–Cancer incidence and mortality was ascertained by linkage to cancer registries and supplemented by hospital records.

–In our analytic cohort, 2,914 incident primary cancers and 1,164 cancer deaths occurred during follow up through 2012.

• Total WBC counts and differentials were assessed at baseline. On average, lymphocyte counts constituted 33% (range: 7% - 86%) of WBC count

–Among Whites: 31% (range: 7% - 82%)

–Among African-Americans: 40% (range: 7% - 86%)

• The normal range for lymphocyte and granulocyte counts was defined as the mean +/- 2 standard deviations

–Race-specific lymphocyte and granulocyte counts were categorized as below the normal range, tertiles within the normal range (first tertile was a reference), and above the normal range.

Statistical Analysis

• Cox proportional hazards regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for overall and site-specific cancer incidence and mortality

- Model 1: Adjusted for age, sex, race, and study center
- Model 2: Model 1 additionally adjusted for education level, alcohol consumption, smoking history, pack years of smoking, BMI and Physical activity
- Model 3: Model 2 additionally adjusted for hypertension, diabetes status, history of CVD, aspirin use and hormone therapy + menopausal status for breast cancer

Figure 1. Association between lymphocyte levels, overall cancer incidence and overall cancer mortality




Figure 2. Association between lymphocyte levels, non-lung cancer incidence and non-lung cancer mortality




Table 1. Association between granulocyte levels, overall cancer incidence and overall cancer mortality.

Overall Cancer Incidence							
Granulocyte Category							
Category	Number of Cases	Q1 (Below normal range)	Q2 (T1 of normal range)	Q3 (T2 of normal range)	Q4 (T3 of normal range)	Q5 (Above Normal Range)	p-trend
		0.86 - 2.05 x 10 ⁹ /L	1.14 - 3.30 X10 ⁹ /L	2.34 - 4.34 x10 ⁹ /L	3.35 - 7.34 x 10 ⁹ /L	6.40 - 8.85 x10 ⁹ / L	
Total Cohort	2914	HR (95%CI)		HR (95%CI)	HR (95%CI)	HR (95%CI)	
Model 1		0.99 (0.77 - 1.28)	1.00 (Reference)	1.10 (1.00 - 1.20)	1.16 (1.06 - 1.28)	1.25 (0.99 - 1.58)	0.02
Model 2		1.02 (0.78 - 1.32)	1.00 (Reference)	1.04 (0.94 - 1.14)	1.04 (0.94 - 1.15)	0.99 (0.77 - 1.26)	0.93
Model 3		1.02 (0.79 - 1.33)	1.00 (Reference)	1.04 (0.94 - 1.15)	1.05 (0.95 - 1.16)	1.00 (0.78 - 1.28)	0.90
Never Smokers	982						
Model 2		1.04 (0.73 - 1.47)	1.00 (Reference)	1.03 (0.89 - 1.20)	0.95 (0.80 - 1.13)	0.92 (0.43 - 1.95)	0.91
Former Smokers	975						
Model 2		0.99 (0.64 - 1.53)	1.00 (Reference)	0.96 (0.82 - 1.13)	0.99 (0.84 - 1.17)	0.72 (0.39 - 1.32)	0.85
Current Smokers	954						
Model 2		1.01 (0.41 - 2.49)	1.00 (Reference)	1.19 (0.95 - 1.49)	1.23 (0.99 - 1.51)	1.19 (0.86 - 1.65)	0.44
Overall Cancer Mortality							
Total Cohort	1164						
Model 1		0.79 (0.49 - 1.29)	1.00 (Reference)	1.30 (1.11 - 1.53)	1.83 (1.57 - 2.13)	2.59 (1.87 - 3.59)	0.001
Model 2		0.88 (0.54 - 1.44)	1.00 (Reference)	1.11 (0.94 - 1.30)	1.34 (1.14 - 1.57)	1.49 (1.07 - 2.09)	0.002
Model 3		0.93 (0.57 - 1.52)	1.00 (Reference)	1.11 (0.94 - 1.31)	1.31 (1.11 - 1.54)	1.39 (0.99 - 1.96)	0.01
Never Smokers	289						
Model 2		0.77 (0.36 - 1.65)	1.00 (Reference)	1.15 (0.87 - 1.52)	1.27 (0.94 - 1.74)	1.85 (0.58 - 5.85)	0.39
Former Smokers	363						
Model 2		0.74 (0.33 - 1.69)	1.00 (Reference)	0.90 (0.68 - 1.17)	1.24 (0.95 - 1.62)	1.18 (0.48 - 2.92)	0.15
Current Smokers	510						
Model 2		2.15 (0.78 - 5.97)	1.00 (Reference)	1.33 (0.97 - 1.82)	1.51 (1.12 - 2.02)	1.71 (1.11 - 2.64)	0.04

Results

• Lymphocyte counts above the normal range were associated with increased overall cancer mortality (HR: 1.44 (95% CI:1.05 - 1.97)), but did not reach statistical significance for overall cancer incidence (HR: 1.26 (95% CI:0.99 - 1.60)).

• When stratified by smoking status, an association was observed among current smokers for both incidence and mortality. Lymphocyte counts above the normal range were associated with increased overall cancer incidence (HR: 1.38 (95% CI:1.00 - 1.89)), and mortality (HR: 1.60 (95% CI:1.06 - 2.42)) (Figure 1).

• The association between increased lymphocyte counts and cancer risk in smokers was not statistically significant when lung cancer cases were excluded (HR: 1.35 (95% CI:0.94 - 1.95) and HR: 1.31 (95% CI:0.75 – 2.30) for non-lung cancer incidence and mortality, respectively) (Figure 2).

• In site specific analyses, lymphocyte counts above the normal range were associated with higher lung cancer mortality (HR: 1.91 (95% CI: 1.14 - 3.19)), but not lung cancer incidence (HR: 1.59 (95% CI: 0.95 - 2.62)). No other site-specific cancer associations were found with increased lymphocyte levels.

• Increased granulocyte counts were associated with increased overall cancer mortality (p-trend = 0.01), but not overall cancer incidence (p-trend=0.90) (Table 1).

• When stratified by smoking status, granulocyte counts above the normal range were associated with increased overall cancer mortality (HR: 1.71 (95% CI:1.11 – 2.64)), but did not reach statistical significance for overall cancer incidence (HR: 1.00 (95% CI:0.78 - 1.28))(Table 1).

Conclusions

• Our findings support existing evidence of a positive association between increased pre-diagnostic lymphocyte counts and increased cancer mortality overall, and increased cancer incidence and mortality in current smokers.

• The association between increased pre-diagnostic lymphocyte counts and cancer risk was attenuated after excluding incident lung cancer cases.

Acknowledgments

Funding: The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. HHSN2682017000011, HHSN2682017000031, HHSN2682017000051, HHSN2682017000041, HHSN2682017000021. Studies on cancer in ARIC are also supported by the National Cancer Institute U01CA164975. This work was additionally supported by P30 CA006973. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. CE Joshu received support from the Prostate Cancer Foundation.

Acknowledgments: The authors thank the staff and participants of the ARIC study for their important contributions. Cancer incidence data have been provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Maryland Department of Health, 201 W. Preston Street, Room 400, Baltimore, MD 21201. We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC) for the funds that helped support the availability of the cancer registry data.